NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

July 29, 2025, NeoGenomics issued a press release reporting its financial results for the second quarter of 2025. Among other items, NeoGenomics reported revenue of $181.3 million, falling short of consensus estimates, and a net loss of $45.1 million. NeoGenomics also reduced its 2025 revenue forecast to a range of $720 million to $726 million, down from a previous estimate of approximately $753 million.  In addition, NeoGenomics lowered its adjusted EBITDA projection to a range of $41 million to $44 million from a prior range of $55 million to $58 million.

On this news, NeoGenomics’ stock price fell $1.21 per share, or 18.73%, to close at $5.25 per share on July 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980